BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations

Women's Health

Volumn 8, Issue 5, 2012, Pages 543-555

  Finch, Amy ^a   Evans, Gareth ^b   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BRCA1; BRCA2; prophylactic salpingo oophorectomy; surgical menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; METHYLTESTOSTERONE; PLACEBO; TESTOSTERONE;

ANDROGEN THERAPY; BONE DENSITY; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR SYSTEM; COGNITION; DRUG SAFETY; FEMALE; GENE MUTATION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; MASTECTOMY; MENOPAUSAL SYNDROME; MENOPAUSE; ONCOGENE; OVARY CANCER; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; SEXUAL FUNCTION; UTERINE TUBE CARCINOMA; WOMEN'S HEALTH;

ANDROGENS; BONE AND BONES; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MENOPAUSE; MIDDLE AGED; MUTATION; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN NEOPLASMS; OVARIECTOMY; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RISK FACTORS; SALPINGOSTOMY;

EID: 84865721642     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.41     Document Type: Review

References (99)

1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
2. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56(1), 265-271 (1995).
3. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
4. Daly MB, Axilbund JE, Buys S et al.; National Comprehensive Cancer Network. Genetic/ familial high risk assessment: breast and ovarian. J. Natl Compr. Canc. Netw. 8(5), 562-594 (2010).
5. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins - Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet. Gynecol. 113(4), 957-966 (2009).
6. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Cancer 1(3-4), 149-156 (2001).
7. Robson M, Hensley M, Barakat R et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol. Oncol. 89(2), 281-287 (2003).
8. Finch A, Metcalfe KA, Chiang JK et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol. Oncol. 121(1), 163-168 (2011).
9. Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100(7), 475-482 (2008).
10. Tuppurainen M, Kröger H, Honkanen R et al. Risks of perimenopausal fractures - a prospective population-based study. Acta Obstet. Gynecol. Scand. 74(8), 624-628 (1995).
11. Challberg J, Ashcroft L, Lalloo F et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: Significant bone health issues in those not taking HRT. Br. J. Cancer 105(1), 22-27 (2011).
12. Rivera CM, Grossardt BR, Rhodes DJ et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16(1), 15-23 (2009).
13. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 316(18), 1105-1110 (1987).
14. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 14(3 Pt 2), 562-566 (2007).
15. Parker WH, Broder MS, Chang E et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet. Gynecol. 113(5), 1027-1037 (2009).
16. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause 19(3), 272-277 (2012).
17. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 289(20), 2673-2684 (2003).
18. Hendrix SL, Wassertheil-Smoller S, Johnson KC et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113(20), 2425-2434 (2006).
19. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: Role of time since menopause and age at initiation of hormone therapy. Arch. Intern. Med. 168(8), 861-866 (2008).
20. Rocca WA, Bower JH, Maraganore DM et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11), 1074-1083 (2007).
21. Shukla PC, Singh KK, Quan A et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat. Commun. 2, 593 (2011).
22. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am. J. Obstet. Gynecol. 204(1), 19e1-19e6 (2011).
23. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122(9), 2017-2022 (2008).
24. Metcalfe KA, Ghadirian P, Rosen B et al. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med. 1(2), E92-E98 (2007).
25. Metcalfe KA, Mian N, Enmore M et al. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res. Treat. 133(2), 735-740 (2012).
26. Skytte AB, Gerdes AM, Andersen MK et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 77(4), 342-349 (2010).
27. Evans DG, Lalloo F, Ashcroft L et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol. Biomarkers Prev. 18(8), 2318-2324 (2009).
28. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl Cancer Inst. 91(17), 1475-1479 (1999).
29. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur. J. Cancer 38(Suppl. 6), S15-S17 (2002).
30. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346(21), 1609-1615 (2002).
31. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296(2), 185-192 (2006).
32. Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J. Clin. Oncol. 23(30), 7491-7496 (2005).
33. Kramer JL, Velazquez IA, Chen BE et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J. Clin. Oncol. 23(34), 8629-8635 (2005).
34. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl Cancer Inst. 101(2), 80-87 (2009).
35. Casey MJ, Synder C, Bewtra C et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol. Oncol. 97(2), 457-467 (2005).
36. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616-1622 (2002).
37. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25(10), 1283-1289 (2001).
38. Powell CB, Kenley E, Chen LM et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23(1), 127-132 (2005).
39. Finch A, Shaw P, Rosen B et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 100(1), 58-64 (2006).
40. Leunen K, Legius E, Moerman P et al. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: Importance of fallopian tube dysplasia. Int. J. Gynecol. Cancer 16(1), 183-188 (2006).
41. Carcangiu ML, Peissel B, Pasini B et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: Report of 6 cases and review of the literature. Am. J. Surg. Pathol. 30(10), 1222-1230 (2006).
42. Laki F, Kirova YM, This P et al. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109(9), 1784-1790 (2007).
43. Hirst JE, Gard GB, McIllroy K et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int. J. Gynecol. Cancer 19(5), 826-829 (2009).
44. Leeper K, Garcia R, Swisher E et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87(1), 52-56 (2002).
45. Lamb JD, Garcia RL, Goff BA et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am. J. Obstet. Gynecol. 194(6), 1702-1709 (2006).
46. Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur. J. Hum. Genet. 17(11), 1381-1385 (2009).
47. Rutter JL, Wacholder S, Chetrit A et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study. J. Natl Cancer Inst. 95(14), 1072-1078 (2003).
48. Chen KT, Schooley JL, Flam MS. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet. Gynecol. 66(Suppl. 3), S93-S94 (1985).
49. Paley PJ, Swisher EM, Garcia RL et al. Occult cancer of the fallopian tube in BRCA- 1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis. Gynecol. Oncol. 80(2), 176-180 (2001).
50. Colgan TJ, Boerner SL, Murphy J et al. Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy. Gynecol. Oncol. 85(3), 397-403 (2002).
51. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J. Clin. Oncol. 25(20), 2921-2927 (2007).
52. Rabban JT, Krasik E, Chen LM et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: Implications for defining an optimal specimen dissection protocol. Am. J. Surg. Pathol. 33(12), 1878-1885 (2009).
53. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30(2), 230-236 (2006).
54. Crum CP, Drapkin R, Miron A et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19(1), 3-9 (2007).
55. Crum CP, Drapkin R, Kindelberger D et al. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 5(1), 35-44 (2007).
56. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum. Pathol. 42(7), 918-931 (2011).
57. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27(2), 151-160 (2008).
58. Leblanc E, Narducci F, Farre I et al. Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA1 or 2 genes? Rationale and preliminary development. Gynecol. Oncol. 121(3), 472-476 (2011).
59. Madalinska JB, Hollenstein J, Bleiker E et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol. 23(28), 6890-6898 (2005).
60. Madalinska JB, van Beurden M, Bleiker EM et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J. Clin. Oncol. 24(22), 3576-3582 (2006).
61. Fang CY, Cherry C, Devarajan K et al. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol. Oncol. 112(3), 594-600 (2009).
62. Finch A, Metcalfe KA, Chiang J et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology doi:10.1002/ pon.2041 (2011) (Epub ahead of print).
63. Campfield Bonadies D, Moyer A, Matloff ET. What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy. Fam. Cancer 10(1), 79-85 (2011).
64. Aitken JM, Hart DM, Anderson JB et al. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. BMJ 2(5862), 325-328 (1973).
65. Pansini F, Bagni B, Bonaccorsi G et al. Oophorectomy and spine bone density: Evidence of a higher rate of bone loss in surgical compared with spontaneous menopause. Menopause 2(2), 109-115 (1995).
66. Cann CE, Genant HK, Ettinger B, Gordan GS. Spinal mineral loss in oophorectomized women. Determination by quantitative computed tomography. JAMA 244(18), 2056-2059 (1980).
67. Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric 14(4), 445-452 (2011).
68. Cohen JV, Chiel L, Boghossian L et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam. Cancer 11(1), 69-75 (2012).
69. Castelo-Branco C, Figueras F, Sanjuan A et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 6(4), 307-311 (1999).
70. Castelo-Branco C, Figueras F, Sanjuan A et al. Long-term postmenopausal hormone replacement therapy effects on bone mass: Differences between surgical and spontaneous patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 83(2), 207-211 (1999).
71. Chapman JS, Powell CB, McLennan J et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Gynecol. Oncol. 122(2), 339-343 (2011).
72. Papaioannou A, Morin S, Cheung AM et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 182(17), 1864-1873 (2010).
73. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293(18), 2257-2264 (2005).
74. Reid L, Blake J, Abramson B, Khan A, Senikas V, Fortier M. Menopause and osteoporosis update. J. Obstet.Gynaecol. Can. 31(Suppl. 1), S1-S45 (2009).
75. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. Menopause 13(2), 265-279 (2006).
76. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
77. Kritz-Silverstein D, Barrett-Connor E, Wingard DL. Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am. J. Public Health 87(4), 676-680 (1997).
78. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: The Framingham study. Ann. Intern. Med. 85(4), 447-452 (1976).
79. Matthews KA, Meilahn E, Kuller LH et al. Menopause and risk factors for coronary heart disease. N. Engl. J. Med. 321(10), 641-646 (1989).
80. Rocca WA, Grossardt BR, de Andrade M et al. Survival patterns after oophorectomy in premenopausal women: A population-based cohort study. Lancet Oncol. 7(10), 821-828 (2006).
81. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 65(2), 161-166 (2010).
82. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen, and cognitive aging: The timing hypothesis. Neurodegener. Dis. 7(1-3), 163-166 (2010).
83. Rocca WA, Bower JH, Maraganore DM et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70(3), 200-209 (2008).
84. Rebbeck TR, Friebel T, Wagner T et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. 23(31), 7804-7810 (2005).
85. Eisen A, Lubinski J, Gronwald J et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J. Natl Cancer Inst. 100(19), 1361-1367 (2008).
86. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat. Rev. Clin. Oncol. 8(11), 669-676 (2011).
87. Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360(6), 573-587 (2009).
88. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004).
89. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 305(13), 1305-1314 (2011).
90. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003).
91. Santen RJ. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Womens Health (Lond. Engl.) 4(3), 207-210 (2008).
92. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343(10), 682-688 (2000).
93. Shifren JL. Androgen deficiency in the oophorectomized woman. Fertil. Steril. 77(Suppl. 4), S60-S62 (2002).
94. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. 49(4), 397-409 (1987).
95. Kotsopoulos J, Narod SA. Androgens and breast cancer. Steroids 77(1-2), 1-9 (2012).
96. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch. Intern. Med. 166(14), 1483-1489 (2006).
97. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch. Intern. Med. 169(1), 41-46 (2009).
98. Jick SS, Hagberg KW, Kaye JA, Jick H. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet. Gynecol. 113(1), 74-80 (2009).
99. Davis SR, Wolfe R, Farrugia H, Ferdinand A, Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J. Sex Med. 6(7), 1850-1856 (2009).